© 2023 MJH Life Sciences and Cancer Network. All rights reserved.
© 2023 MJH Life Sciences™ and Cancer Network. All rights reserved.
October 27, 2022
Dr Joseph Mikhael and Dr Hakan Kaya provide advice for community oncologists who use selinexor and discuss the future of selinexor in patients with R/R MM.
October 20, 2022
Two experienced clinicians share their thoughts on the safety of selinexor, including how they optimize dosing to prioritize patient comfort.
Dr Mikhael and Dr Kaya discuss the clinical implications and share their thoughts on the use of selinexor, carfilzomib and dexamethasone in patients with R/R MM.
October 13, 2022
Dr Mikhael reviews the baseline characteristics, study design and key efficacy and safety data of selinexor, carfilzomib, dexamethasone (XKd) in patients with relapsed/refractory multiple myeloma who are non-refractory to carfilzomib.
Joseph Mikhael, MD, provides a brief overview of the relapsed/refractory multiple myeloma landscape and explains the mechanism of action of selinexor.